Tranilast inhibits pulmonary fibrosis by suppressing TGFβ/SMAD2 pathway

Motoyasu Kato, Fumiyuki Takahashi, Tadashi Sato, Yoichiro Mitsuishi, Ken Tajima, Hiroaki Ihara, Fariz Nurwidya, Hario Baskoro, Akiko Murakami, Isao Kobayashi, Moulid Hidayat, Naoko Shimada, Shinichi Sasaki, Reiko Mineki, Tsutomu Fujimura, Toshio Kumasaka, Shin Ichiro Niwa, Kazuhisa Takahashi

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)

Abstract

Purpose: Idiopathic pulmonary fibrosis (IPF) is characterized by the accumulation of extracellular matrix (ECM) protein in the lungs. Transforming growth factor (TGF) β-induced ECM protein synthesis contributes to the development of IPF. Tranilast, an anti-allergy drug, suppresses TGFβ expression and inhibits interstitial renal fibrosis in animal models. However, the beneficial effects of tranilast or its mechanism as a therapy for pulmonary fibrosis have not been clarified. Methods: We investigated the in vitro effect of tranilast on ECM production and TGFβ/ SMAD2 pathway in TGFβ2-stimulated A549 human alveolar epithelial cells, using quantitative polymerase chain reaction, Western blotting, and immunofluorescence. In vitro observations were validated in the lungs of a murine pulmonary fibrosis model, which we developed by intravenous injection of bleomycin. Results: Treatment with tranilast suppressed the expression of ECM proteins, such as fibro-nectin and type IV collagen, and attenuated SMAD2 phosphorylation in TGFβ2-stimulated A549 cells. In addition, based on a wound healing assay in these cells, tranilast significantly inhibited cell motility, with foci formation that comprised of ECM proteins. Histological analyses revealed that the administration of tranilast significantly attenuated lung fibrosis in mice. Furthermore, tranilast treatment significantly reduced levels of TGFβ, collagen, fibronectin, and phosphory-lated SMAD2 in pulmonary fibrotic tissues in mice. Conclusion: These findings suggest that tranilast inhibits pulmonary fibrosis by suppressing TGFβ/SMAD2-mediated ECM protein production, presenting tranilast as a promising and novel anti-fibrotic agent for the treatment of IPF.

Original languageEnglish
Pages (from-to)4593-4603
Number of pages11
JournalDrug Design, Development and Therapy
Volume14
DOIs
Publication statusPublished - 2020

Keywords

  • Idiopathic pulmonary fibrosis
  • SMAD2
  • TGFβ
  • Tranilast

Fingerprint

Dive into the research topics of 'Tranilast inhibits pulmonary fibrosis by suppressing TGFβ/SMAD2 pathway'. Together they form a unique fingerprint.

Cite this